GlassScriptPhysician profile
Robyn Brianna Mccarty
NPI 1932860129
$3,189.62
in general payments reported to CMS, 2019-2025
30 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $133 · 2023: $851 · 2024: $900 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,053 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,052.53 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $743.94 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $471.30 | 2022-2025 | Tavneos, Tepezza, Evenity |
| Corcept Therapeutics | $318.62 | 2024-2025 | Korlym |
| Lilly USA, LLC | $277.77 | 2023-2025 | Jardiance, Baqsimi, Mounjaro |
| Insulet Corporation | $232.18 | 2024-2025 | Omnipod |
| Shield Therapeutics INC | $166.63 | 2023-2025 | Accrufer |
| Medtronic, INC. | $110.02 | 2022-2025 | Minimed 780g |
| Axsome Therapeutics, INC. | $106.39 | 2024 | Auvelity |
| Tandem Diabetes Care, INC. | $84.09 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Phathom Pharmaceuticals, INC. | $83.98 | 2024-2025 | Voquezna |
| Abbvie INC. | $79.53 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.52 | 2023-2025 | |
| Astellas Pharma US INC | $58.46 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $57.87 | 2023 | Nucala |
| Madrigal Pharmaceuticals | $45.88 | 2025 | Rezdiffra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $41.64 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.43 | 2024-2025 | Jardiance |
| Echosens North America, INC. | $31.70 | 2025 | Fibroscan |
| Sequel Med Tech, LLC | $18.78 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $18.18 | 2023 | Xarelto |
| Ironwood Pharmaceuticals, INC | $17.88 | 2024 | |
| Merck Sharp & Dohme LLC | $17.47 | 2022 | |
| Vanda Pharmaceuticals INC. | $16.07 | 2025 | Hetlioz, Fanapt |
| Antares Pharma, INC. | $16.01 | 2023 | Nocdurna, Tlando, Xyosted |
| Pfizer INC. | $14.93 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $14.61 | 2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $14.58 | 2025 | Breztri |
| Mannkind Corporation | $14.14 | 2024 | |
| Sanofi-Aventis U.S. LLC | $12.98 | 2023 | |
| Endogastric Solutions, INC | $12.04 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.